Dog Immune-Mediated Hemolytic Anemia Emergency

IMHA is a life-threatening autoimmune destruction of red blood cells requiring rapid diagnosis and aggressive immunosuppressive treatment.

Key Facts

IMHA occurs when the immune system attacks red blood cells, causing severe hemolytic anemia
Primary IMHA has no identified underlying cause; secondary IMHA is triggered by drugs, infections, or cancer
Clinical signs include pale to yellow gums, weakness, rapid breathing, and collapse
Diagnosis uses blood smear (spherocytes, autoagglutination) and Coombs test
Treatment requires rapid immunosuppression with prednisone plus adjunctive drugs like mycophenolate
Blood transfusions provide life-saving support while immunosuppression takes effect
Mortality rates of 20-50% make IMHA one of the most serious veterinary emergencies

Welfare Considerations

IMHA causes acute severe anemia with profound weakness, breathlessness, and cardiovascular compromise. The rapidity of red blood cell destruction means dogs can deteriorate within hours. The treatment itself - high-dose immunosuppression - creates risks of infection and other complications. Dogs surviving the acute phase face weeks of careful monitoring and medication tapering. Welfare requires both rapid emergency treatment and attentive monitoring during the prolonged recovery period.

What You Can Do

Recognize pale gums, yellow tinge, and sudden collapse in dogs as emergency signs requiring immediate vet care
Seek specialist internal medicine referral for IMHA management - outcomes improve with expert care
Follow immunosuppressive tapering schedules carefully - too rapid reduction causes relapse
Monitor complete blood counts at the frequency recommended during treatment to track response
Report any signs of infection promptly as immunosuppressed IMHA dogs are highly susceptible
Connect with IMHA support groups for guidance on the prolonged management period